CWC-19769-55132
3 vaccinations
3 coded responses
29 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 61-65
- ZIP prefix
- 786 / TX
- Registered
- 2021-04-17
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-17
Registered in v-safe
-
2021-04-17
Dose 1 — Pfizer-BioNTech
- 2021-04-17
-
2021-04-19
Health check-in — days 1–6 daily, dose 1Feeling: Good · Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
-
2021-04-20
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-04-21
- 2021-04-22
- 2021-04-23
- 2021-04-24
- 2021-05-01
-
2021-05-08
Dose 2 — Pfizer-BioNTech
- 2021-05-08
-
2021-05-09
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-05-10
- 2021-05-11
- 2021-05-12
- 2021-05-13
- 2021-05-14
- 2021-05-15
- 2021-05-22
- 2021-05-29
- 2021-06-05
- 2021-06-12
- 2021-06-19
-
2021-08-07
Survey response — 3 months, dose 2MedDRA: Adverse reaction, Alpha-1 antitrypsin deficiency carrier, Dyspnoea, Hepatic steatosis, Office visit, Protein total decreased — Feeling: Good · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Symptoms: Trouble breathing. Went to see a pulmonary doctor I have been diagnosed as a Alpha One carrier. I also have symptoms of the disease and my levels are low in the protein that my liver is supposed to be making to protect my lungs. Fatty liver · Healthcare visit (other): Doctors office/CT ScanMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-08-07
Report sent to call center — 3 months, dose 2Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-10-07
Dose 3 — Pfizer-BioNTech
-
2021-11-06
Survey response — 6 months, dose 2MedDRA: Alpha-1 antitrypsin deficiency carrier — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Alpha-1 Antitrypsin deficiency/carrier now taking weekly Glassia Infusion Received 3rd Covid-19 Shot on October 7th, 2021MedDRA releases: 2024-11 · check-in free text available
- 2021-11-08
- 2021-11-11
- 2021-11-18
-
2021-11-23
Call successfulParticipant prefers to complete VAERS report online
- 2022-01-08
- 2022-04-07
-
2022-10-07
Survey response — 12 months, dose 3MedDRA: Alpha-1 antitrypsin deficiency, Unevaluable event — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Symptoms: Diagnosed with Alpha-1 Antitrypsin Deficiency · Healthcare visit (other): Glassia infusions weeklyMedDRA releases: 2024-11 · check-in free text available
-
2022-10-07
Report sent to call center — 12 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
-
2022-10-11
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-17 | Pfizer-BioNTech | |
| 2 | 2021-05-08 | Pfizer-BioNTech | |
| 3 | 2021-10-07 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 successful
Free text
Release 9 — 3 months, dose 2
Symptoms: Trouble breathing. Went to see a pulmonary doctor I have been diagnosed as a Alpha One carrier. I also have symptoms of the disease and my levels are low in the protein that my liver is supposed to be making to protect my lungs. Fatty liver
Healthcare visit (other): Doctors office/CT Scan
Release 10 — 6 months, dose 2
Symptoms: Alpha-1 Antitrypsin deficiency/carrier now taking weekly Glassia Infusion Received 3rd Covid-19 Shot on October 7th, 2021
Release 12 — 12 months, dose 3
Symptoms: Diagnosed with Alpha-1 Antitrypsin Deficiency
Healthcare visit (other): Glassia infusions weekly
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Office visit | ✓ | · | ✓ |
| HCVO | Unevaluable event | · | · | ✓ |
| SD | Adverse reaction | ✓ | · | ✓ |
| SD | Alpha-1 antitrypsin deficiency | · | · | ✓ |
| SD | Alpha-1 antitrypsin deficiency carrier | ✓ | · | ✓ |
| SD | Dyspnoea | ✓ | · | ✓ |
| SD | Hepatic steatosis | ✓ | · | ✓ |
| SD | Protein total decreased | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release